Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.

J Psychedelic Stud · 2017 · PMC6157925 · PMID 30272050

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In two Phase I studies, low doses of noribogaine (the active metabolite of ibogaine, which has a distinct pharmacological profile) was well tolerated ( Glue et al., 2015 ) and showed a trend toward reduction in opioid withdrawal ratings ( Glue et al., 2016 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.